Rockwell's Triferic OK'd, but without ESA-sparing use
This article was originally published in Scrip
Rockwell Medical revealed on 26 January it had won approval from the FDA to market Triferic (ferric pyrophosphate) as a replacement of iron to maintain hemoglobin in adults with hemodialysis-dependent chronic kidney disease.
You may also be interested in...
Asia Deal Watch: BeiGene Gets Chinese Rights To Two EUSA Rare Disease Therapies
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
Finance Watch: Rough US Stock Market Doesn't Stop Biopharma IPOs As Six More Go Public
October has not been kind to biotech stocks, but that hasn't stopped drug developers from launching IPOs in the US. Also, Takeda reconfigures debt ahead of Shire deal and other offerings.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.